FDA's Generic Mifepristone Approval Sparks Fierce Pro-Life Backlash

A pro-life organisation has strongly criticised the FDA's recent approval of a generic version of the abortion drug mifepristone. Susan B. Anthony Pro-Life America called the decision 'unconscionable', arguing it undermines states' rights and expands access to what they describe as a dangerous medication. The move has also drawn opposition from conservative groups and the states of Missouri, Kansas, and Idaho.

The FDA approved the generic mifepristone in October 2025, a decision that critics claim was legally required but still controversial. Kelsey Pritchard, Political Communications Director for Susan B. Anthony Pro-Life America, highlighted the drug's reported complications, including haemorrhage, infection, and the need for emergency surgery. She also noted that generic drugs do not require independent safety and effectiveness data, raising concerns about oversight.

Andrew Nixon, HHS Communications Director, confirmed that the FDA has limited flexibility in approving generics, as applicants are not required to submit new evidence. However, he added that the Department of Health and Human Services is reviewing reported adverse effects to assess whether the drug's risk mitigation measures remain adequate.

Pritchard further criticised the original approval of mifepristone under President Bill Clinton, claiming pregnancy was wrongly classified as an illness to fast-track its release. While she acknowledged that HHS Secretary Kennedy and FDA Commissioner Makary have pledged to review updated safety data, she argued they could immediately reinstate stricter regulations from President Trump's first term.

The organisation insists abortion is the leading cause of death in the U.S., with over 60% of procedures now involving abortion drugs. They are demanding a full revocation of mifepristone's approval.

The FDA's decision has intensified the debate over abortion access and drug safety. Conservative groups and opposing states continue to push for stricter controls, while federal agencies maintain that existing regulations follow standard approval procedures. The dispute is likely to remain a focal point in ongoing legal and political battles over reproductive rights.